Mufg Securities Americas Inc. Buys Shares of 29,939 Bristol-Myers Squibb (NYSE:BMY)

Mufg Securities Americas Inc. purchased a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 29,939 shares of the biopharmaceutical company's stock, valued at approximately $1,693,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Nearwater Capital Markets Ltd acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $15,837,000. NorthRock Partners LLC lifted its holdings in shares of Bristol-Myers Squibb by 192.8% during the 4th quarter. NorthRock Partners LLC now owns 26,839 shares of the biopharmaceutical company's stock valued at $1,518,000 after acquiring an additional 17,672 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 16.1% during the 4th quarter. Nuveen Asset Management LLC now owns 10,420,945 shares of the biopharmaceutical company's stock valued at $589,409,000 after acquiring an additional 1,444,822 shares in the last quarter. Morse Asset Management Inc lifted its holdings in shares of Bristol-Myers Squibb by 562.9% during the 4th quarter. Morse Asset Management Inc now owns 66,292 shares of the biopharmaceutical company's stock valued at $3,749,000 after acquiring an additional 56,292 shares in the last quarter. Finally, Leigh Baldwin & CO. LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $30,207,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Up 2.1%

Shares of BMY traded up $0.96 during midday trading on Friday, hitting $46.77. The company had a trading volume of 12,103,063 shares, compared to its average volume of 13,242,297. The company's 50 day moving average price is $53.05 and its 200 day moving average price is $55.97. The stock has a market cap of $95.18 billion, a price-to-earnings ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the firm earned ($4.40) EPS. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.30%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.09% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on BMY. UBS Group reduced their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Finally, Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.